Related references
Note: Only part of the references are listed.Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma
P. Bhavsar et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
A Randomized, Placebo-Controlled Study of the Effects of the p38 MAPK Inhibitor SB-681323 on Blood Biomarkers of Inflammation in COPD Patients
Dave Singh et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Inhibition of p38: Has the Fat Lady Sung
Mark C. Genovese
ARTHRITIS AND RHEUMATISM (2009)
Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD
D. A. Lomas et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Glucocorticoid resistance in inflammatory diseases
Peter J. Barnes et al.
LANCET (2009)
Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study
G. Engstrom et al.
THORAX (2009)
The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease
Don D. Sin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Increased systemic inflammation is a risk factor for COPD exacerbations
Karin H. Groenewegen et al.
CHEST (2008)
Systemic inflammation and COPD - The Framingham Heart Study
Robert E. Walter et al.
CHEST (2008)
Increased activation of p38 MAPK in COPD
T. Renda et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Biomarkers of Systemic Inflammation in Stable and Exacerbation Phases of COPD
Fisun Karadag et al.
LUNG (2008)
Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort
D. A. Lomas et al.
THORAX (2008)
Practical usage of O'Brien's OLS and GLS statistics in clinical trials
Nigel S. Dallow et al.
PHARMACEUTICAL STATISTICS (2008)
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - GOLD executive summary
Klaus F. Rabe et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects
J. S. Lakind et al.
BIOMARKERS (2007)
Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease
NC Barnes et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
C-reactive protein in patients with COPD, control smokers and non-smokers
VM Pinto-Plata et al.
THORAX (2006)
COPD, a multicomponent disease: implications for management
AGN Agusti
RESPIRATORY MEDICINE (2005)
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis
WQ Gan et al.
THORAX (2004)
Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease
M Dahl et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial
CE Brightling et al.
LANCET (2000)
Share Paper
